Clinical Severity of Diabetic Ketoacidosis by SGLT2 Inhibitors Use: A Retrospective Observational Study
Diabetes/Metabolism Research and Reviews · 2026
DOI: 10.1002/dmrr.70226 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2026. Verfasst von Mor Naaman und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Sodium-Glucose Transporter 2 Inhibitors, Severity of Illness Index, Diabetes Mellitus, Type 2. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are commonly used glucose lowering agents with established cardiac and kidney benefits. Diabetic ketoacidosis (DKA) is a rare complication associated with their use, which entails significant morbidity and mortality. Materials and Methods This retrospective observational study included patients with diabetes (any) admitted with DKA to a large tertiary hospital. Demographic, clinical and laboratory data were extracted from electronic medical records. Outcomes included DKA severity as determined by nadir pH, duration of stay, need for intensive care (ICU) and inpatient mortality.
Results
Baseline SGLT2i use was documented in 27/191 patients (14.1%). SGLT2i users had lower nadir pH (7.08 ± 0.15 vs. 7.15 ± 0.12, p = 0.006) and were more likely to have severe DKA (29.6% vs. 12.2%, p = 0.007). After adjusting for multiple covariates, SGLT2i use remained independently associated with DKA severity. ICU admission and hospitalisation duration did not differ between the groups. Inpatient mortality occurred in 3/27 users and 3/164 non‐users, while the composite outcome of mortality and/or ICU admission was similar (74.1% vs. 72.0%, p = 0.819). Findings remained consistent after excluding patients with new‐onset diabetes.
Conclusions
Among patients hospitalised with DKA in a large tertiary centre, SGLT2i use was associated with a more severe biochemical presentation, reflected by a lower nadir pH. The observed difference in inpatient mortality was based on few events and should be interpreted cautiously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Orthopedics, Hadassah Medical Center, Jerusalem, Israel.
- School of Pharmacology, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Hebrew University Hospital, Jerusalem, Israel.
- Internal Medicine Department A, Hadassah Hebrew University Hospital, Jerusalem, Israel.
ORCID-Profile: Avivit Cahn
Zitieren
APA
Naaman, M., Fisher-Negev, T., Aharon-Hananel, G., Harel, T., & Cahn, A. (2026). Clinical Severity of Diabetic Ketoacidosis by SGLT2 Inhibitors Use: A Retrospective Observational Study. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70226
Vancouver
Naaman M, Fisher-Negev T, Aharon-Hananel G, Harel T, Cahn A. Clinical Severity of Diabetic Ketoacidosis by SGLT2 Inhibitors Use: A Retrospective Observational Study. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70226
BibTeX
@article{Naaman2026,
author = {Naaman, Mor and Fisher-Negev, Tamar and Aharon-Hananel, Genya and Harel, Tehila and Cahn, Avivit},
title = {Clinical Severity of Diabetic Ketoacidosis by SGLT2 Inhibitors Use: A Retrospective Observational Study},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
doi = {10.1002/dmrr.70226}
}
EUVIMED